Circulating tumor cells (CTCs) are specialized rare cells, which have been shed from a primary solid tumor of the body and circulate in the vasculature system of the body, eventually causing metastasis. CTCs act as the seeds for successive development of additional metastatic tumors in distant organs, which is liable for the majority of cancer-related deaths. On the other hand, these fatal rare cells are capable of providing useful information of cancer patients, since their monitoring and detection is valuable for predicting the response to treatment and prognosis as well as staging of the disease. These rare cells are found both in the bone marrow and in peripheral blood of the body. However, the CTCs found in the blood usually have a short survival time as compared to CTCs found in the bone marrow, which makes the analysis of blood sample for CTCs more specific, thus known as “liquid biopsy”. Therefore, detection of CTCs during the progression of the tumor provides a prognostic value of the tumor progression as well as evaluates the efficacy of therapeutic intervention and provides necessary information for developing personalized medicines.
Request a Sample Copy of the Report @ http://www.mrrse.com/sample/1245
The primary factors driving the growth of the CTCs prognostic technologies market are increasing demand for diagnostic and prognostic technologies coupled with high incidence and prevalence rates of cancer. Furthermore, colossal application scope of these technologies and patient safety are also some of the factors driving the growth of the CTCs prognostic technologies market. Additionally, substantial cost benefit ratio of these technologies and wide use in therapeutic monitoring are some of the other significant factors that are expected to fuel the growth of the CTCs technologies globally. However, some of the important factors that are restraining the growth of this market are high pricing associated with the technologies and stringent regulatory policies.
Inquiry on this report @ http://www.mrrse.com/enquiry/1245
The CTCs prognostic technologies market is categorized based on technology and applications. The technology market has been further segmented into tumor cell enrichment and tumor cell detection. Moreover, the tumor cell enrichment market is further segmented into filtration, centrifugation and immunomagnetic methods, among which immunomagnetic methods accounted for the largest market due to commercial availability and high adoption rate for these techniques. Moreover, the tumor cell detection market is further bifurcated into molecular methods and optical methods. Furthermore, these technologies are usually applied in breast cancer, prostate cancer and colorectal cancer as well as other types of cancer (e.g. lung cancer, ovarian cancer and pancreas cancer); among which, breast cancer is expected to witness the highest growth during the forecast period. This growth can be attributed to the increasing prevalence rate of breast cancer and high adoption rate. However, it is also expected that other types of cancer (e.g. colorectal, lung, pancreas and ovarian) will account for a significant share of the market due to their rising prevalence rates and increasing research and development activities for developing personalized medicine.
Read Complete Report with TOC @ http://www.mrrse.com/ctcs-prognostic-technologies-market
North America is the largest market for CTCs prognostic technologies owing to the high prevalence and incidence rate of cancer as well as high adoption rate for advanced prognostic technologies. However, low commercial availability of these technologies and high development cost of the technologies are some of the factors that have led to the sluggish growth of this market. However, other regions such as Asia-Pacific is also estimated to show an appreciable growth rate owing to the expected rise in various types of cancer coupled with high research and development initiatives and growing adoption rate for advanced therapeutic monitoring technologies.
AdnaGen AG, Epic Sciences, Inc., Fluxion Biosciences, Inc., Silicon Biosystems, S.p.A., Rarecells USA, Inc., Veridex, LLC and Vitatex Inc. are major companies leading the circulating tumor cells (CTCs) prognostic technologies market.
90 State Street,
Albany NY – 12207